ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1620

Unveiling of a New Molecular Imaging Biomarker? Vascular Adhesion Protein-1 and [68Ga]Ga-DOTA-Siglec-9 PET/CT in Detecting Giant Cell Arteritis Relapse

Simon Petzinna1, Jim Küppers2, Benedikt Schemmer2, Anna Kernder3, Claus Juergen Bauer1, Pantelis Karakostas1, Denada Bruci3, Adina Morar3, Anja Winklbauer2, Markus Essler2 and Valentin S. Schäfer2, 1Clinic of Internal Medicine III, Department of Rheumatology, University Hospital of Bonn, Bonn, Germany, Bonn, Germany, 2University Hospital Bonn, Bonn, Germany, 3University Hospital Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany

Meeting: ACR Convergence 2024

Keywords: giant cell arteritis, Imaging, immunology, Nuclear Medicine, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Vascular adhesion protein-1 (VAP-1) is a transmembrane adhesion molecule with oxidative deamination functionality, which is expressed in vascular smooth muscle cells and endothelial cells. Under inflammatory conditions, VAP-1 rapidly translocates to the cell surface, facilitating leukocyte adhesion and migration via its interaction with Siglec-9, a ligand upregulated on neutrophils and monocytes during inflammation. A soluble form of VAP-1 (sVAP-1) contributes to the circulating monoamine oxidase activity in human blood and further influences leukocyte migration. The novel radiotracer [68Ga]Ga-DOTA-Siglec-9 may improve the assessment of giant cell arteritis (GCA), as only being upregulated in inflammation. This study is the first to evaluate the diagnostic value and investigate the role of Siglec-9 and sVAP-1 in patients with relapsing GCA.

Methods: Patients with relapsing GCA underwent [68Ga]Ga-DOTA-Siglec-9-PET/CT. Additionally, GCA patients and healthy controls underwent laboratory testing, including sVAP-1 determination and Siglec-9 expression analysis. sVAP-1 levels were quantified using enzyme-linked immunosorbent assay (ELISA). Siglec-9 expression was assessed via flow cytometry (FACS) on peripheral blood mononuclear cells, which included CD3+CD4+ (CD4 T cells), CD3+CD8+ (CD8 T cells), CD14+CD16- (classical monocytes), CD14+CD16+ (intermediate monocytes), CD14-CD16+ (non-classical monocytes), CD19-CD38+CD138+ (plasma cells), CD19+CD38+ (plasmablasts), CD19+CD38- (naive B cells), and CD38+CD16+ (NK cells). Comparisons of sVAP-1 levels and Siglec-9 expression between GCA relapse patients and healthy controls were performed. Furthermore, associations between the maximum standardized uptake value (SUVmax) of the aorta and subclavian/ axillary artery with sVAP-1 levels and Siglec-9 expression were analyzed.

Results: Eight patients with relapsing GCA and eight healthy controls were enrolled (Tbl.1). The [68Ga]Ga-DOTA-Siglec-9 PET scan demonstrated increased localized SUVmax in the subclavian/ axillary artery and aorta (Fig. 1). ELISA showed significantly elevated sVAP-1 in GCA relapse patients compared to the control group (p = .0198). FACS revealed significantly increased Siglec-9 expression on CD4/ CD8 T cells, classical, intermediate, and non-classical monocytes, plasma cells, plasmablasts, and NK cells in relapsed patients compared to controls (p < .0001), while naïve B cells showed no difference (p = .8885) (Tbl. 2). No significant association was found between sVAP-1, Siglec-9 and tracer uptake (data not shown).

Conclusion: This study is the first to demonstrate that [68Ga]Ga-DOTA-Siglec-9-PET/CT can detect inflammatory activity in patients with relapsing GCA. The elevated levels of sVAP-1 and increased Siglec-9 expression on various immune cell subsets raise questions regarding their pathophysiological significance and potential roles as biomarkers in GCA. Further research is warranted to deepen our understanding of VAP-1 and Siglec-9 in GCA.

Supporting image 1

Figure 1: [68Ga]Ga-DOTA-Siglec-9-PET/CT Imaging Findings in Giant Cell Arteritis Patients with Relapse.
This figure illustrates [68Ga]Ga-DOTA-Siglec-9-PET/CT imaging results from eight patients experiencing a relapse of giant cell arteritis. Patient-specific tracer uptakes are revealed in the aorta and subclavian/ axillary artery. The patients are ordered ascendingly based on their aortic tracer uptake. The labels A-H correspond to the patient numbers listed in Table 1.

Supporting image 2

Table 1: Demographic, Clinical, and Laboratory Data and Relative Tracer Uptake in [68Ga]Ga-DOTA-Siglec-9-PET/CT in the Aorta and Subclavian/ Axillary Artery in Giant Cell Arteritis Patients with Relapse.
This table presents the demographic, clinical, and laboratory data of eight patients experiencing relapses of giant cell arteritis. It includes age, sex, administered prednisolone dose in the 7 days prior to the scan, CRP level, sVAP_1 levels, and relative tracer uptake in [68Ga]Ga-DOTA-Siglec-9-PET/CT in the aorta and subclavian/ axillary artery. The labels A-H correspond to the patient numbers listed in Figure 1. Abbreviations: mg: milligram; CRP: C-reactive protein; sVAP_1: soluble vascular adhesion protein_1; ng: nanogram; l: liter; SUV: standard uptake value.

Supporting image 3

Table 2: Relative Expression of Siglec-9 on Various Cell Lines in Giant Cell Arteritis Patients with Relapse and Healthy Controls.
This table presents the relative Siglec-9 expression on peripheral blood mononuclear cells in eight patients and three healthy controls. The cell lines examined include CD3+CD4+ (CD4 T cells), CD3+CD8+ (CD8 T cells), CD14+CD16- (classical monocytes), CD14+CD16+ (intermediate monocytes), CD14-CD16+ (non-classical monocytes), CD19-CD38+CD138+ (plasma cells), CD19+CD38+ (plasmablasts), CD19+CD38- (naïve B cells), and CD38+CD16+ (NK cells) Siglec-9 expression was significantly higher on CD4 T cells, CD8 T cells, classical, intermediate, and non-classical monocytes, plasma cells, plasmablasts, and NK cells in relapsed patients compared to controls, while naïve B cells showed no significant difference. The labels A-H correspond to the patient numbers listed in Figure 1. Statistical significance (p-values) and estimates (ß) for the differences between patients and healthy controls are provided. Abbreviations: CD: cluster of differentiation, HC: healthy control.


Disclosures: S. Petzinna: None; J. Küppers: None; B. Schemmer: None; A. Kernder: None; C. Bauer: None; P. Karakostas: None; D. Bruci: None; A. Morar: None; A. Winklbauer: None; M. Essler: None; V. Schäfer: None.

To cite this abstract in AMA style:

Petzinna S, Küppers J, Schemmer B, Kernder A, Bauer C, Karakostas P, Bruci D, Morar A, Winklbauer A, Essler M, Schäfer V. Unveiling of a New Molecular Imaging Biomarker? Vascular Adhesion Protein-1 and [68Ga]Ga-DOTA-Siglec-9 PET/CT in Detecting Giant Cell Arteritis Relapse [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/unveiling-of-a-new-molecular-imaging-biomarker-vascular-adhesion-protein-1-and-68gaga-dota-siglec-9-pet-ct-in-detecting-giant-cell-arteritis-relapse/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/unveiling-of-a-new-molecular-imaging-biomarker-vascular-adhesion-protein-1-and-68gaga-dota-siglec-9-pet-ct-in-detecting-giant-cell-arteritis-relapse/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology